Simona Zito
Overview
Explore the profile of Simona Zito including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guerrizio M, Zito S, Mammarella F, Frulio R, Trotta M, Da Cas R, et al.
Ann Ist Super Sanita
. 2023 Dec;
59(4):271-279.
PMID: 38088394
Introduction: In the last decade, the significant expenditure and consumption increase of vitamin D in Italy led some regions to adopt strategies to improve prescribing appropriateness and contain expenditure. Materials...
2.
Moretti G, Vinci B, Zito S, Caputo A, Attanasio F, Vainieri M
PLoS One
. 2023 Sep;
18(9):e0291628.
PMID: 37708187
Introduction: Low Molecular Weight Heparins (LMWHs) and Fondaparinux have been widely used as anticoagulants. Mass prescription may lead to prescriptive inappropriateness, which causes Heparin-induced thrombocytopenia and other side effects. Objectives:...
3.
Marano G, Da Cas R, Zito S, Ippoliti I, Fortinguerra F, Pierantozzi A, et al.
Recenti Prog Med
. 2023 Apr;
114(5):268-276.
PMID: 37114608
In 2021, the national expenditure for blood coagulation factors was 541.4 million, growing steadily over the past decade. Hemophilia A is the congenital hemorrhagic disease with the highest drug consumption...
4.
Marano G, Da Cas R, Zito S, Ippoliti I, Cangini A, Pierantozzi A, et al.
Recenti Prog Med
. 2023 Apr;
114(5):258-267.
PMID: 37114607
Therapeutic strategies for the treatment of congenital bleeding disorders. Congenital hemorrhagic diseases (CHDs) are a group of rare disorders caused by quantitative or qualitative deficiency of one or more coagulation...
5.
Marengoni A, Cangini A, Pierantozzi A, Onder G, Da Cas R, Ippoliti I, et al.
Aging Clin Exp Res
. 2023 Mar;
35(4):905.
PMID: 36897557
No abstract available.
6.
Marengoni A, Cangini A, Pierantozzi A, Onder G, Da Cas R, Ippoliti I, et al.
Aging Clin Exp Res
. 2022 Dec;
35(2):443-453.
PMID: 36469252
Objective: This study aims to analyse the impact of the pandemic on the amount of use and new medication dispensation for chronic diseases in the Italian population aged 65 years...
7.
Zazzara M, Cangini A, Da Cas R, Ippoliti I, Marengoni A, Pierantozzi A, et al.
Front Pharmacol
. 2022 Apr;
13:818875.
PMID: 35370651
Older adults are often affected by multiple chronic conditions and experience geriatric syndromes that may affect the risk/benefit profile of medications. Little is known about the use of such medications...
8.
Zito S, Pierantozzi A, Marinelli M, Ambrosino F, Trotta F, Cangini A
Recenti Prog Med
. 2022 Feb;
113(2):76-83.
PMID: 35156949
The "National Report on Medicines use in older adults in Italy. Year 2019" provides a summary of data concerning the expenditure and consumption of medicines in individuals aged 65 or...
9.
Zito S, Fortinguerra F, Pierantozzi A, Ambrosino F, Traversa G, Trotta F, et al.
Recenti Prog Med
. 2021 Oct;
112(10):659-667.
PMID: 34647536
The 2020 National Report "Medicines use in Italy", produced by the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA), describes the Italian pharmaceutical assistance...
10.
Zito S, De Fiore R, Marini R, Cangini A, Perna S, Settesoldi D
Recenti Prog Med
. 2021 Jul;
112(7):504-509.
PMID: 34263877
The results of the OsMed reports of the Italian Medicines Agency (AIFA) on consumption and expenditure related to biosimilar medicines show a high heterogeneity at the regional level, with great...